Lirentelimab provides favorable outcomes in severe allergic conjunctivitis: Study
USA: Lirentelimab was very well tolerated and can relieve severe allergic conjunctivitis (AC), atopic symptoms, and decrease inflammatory mediators in patient's tears, says an article published in The Journal of Allergy and Clinical Immunology.
Allergic conjunctivitis is a chronic inflammatory ocular condition caused by eosinophils and mast cells that is commonly characterized by severe itching, watering or mucous discharge, discomfort, burning in both eyes, and redness and swelling of the conjunctiva. Atopic keratoconjunctivitis (AKC), vernal keratoconjunctivitis (VKC), and perennial allergic conjunctivitis are all severe variants of AC (PAC). AC disease processes entail an inflammatory response, with eosinophils and mast cells serving as major effector cells. Stephen D. Anesi and colleagues present the findings of a phase 1b, open-label research in patients with severe and chronic AC to explore the safety, tolerability, preliminary effectiveness, and pharmacodynamics (PD) of up to 6 monthly doses of lirentelimab.
Patients with chronic, extremely symptomatic atopic keratoconjunctivitis, vernal keratoconjunctivitis, and perennial AC who had a history of topical or systemic corticosteroid therapy were enrolled to receive up to 6 monthly lirentelimab infusions (dosage 1: 0.3 mg/kg, dose 2: 1 mg/kg, following doses: 1 or 3 mg/kg). Changes in peripheral blood eosinophils from baseline, changes in patient-reported symptoms, changes in investigator-reported changes in quality of life, ocular signs and symptoms, and changes in tear cytokine and chemokine levels were also evaluated in people suffering from severe and chronic AC.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.